

CSD/BSE&NSE/2025-26  
January 19, 2026

To  
The Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001  
**Scrip Code: 543064**

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051  
**Scrip Symbol: COHANCE**

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding appointment of Senior Management Personnel**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that the Board of Directors of the Company, based on the recommendations of the Nomination and Remuneration Committee, by way of Circular Resolution passed today, i.e. January 19, 2026, has approved the appointment of Mr. Sunil Kumar Singh, Chief Quality Officer, as Senior Management Personnel of the Company, with effect from January 19, 2026. The brief profile of Mr. Sunil is annexed with this disclosure.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 on the captioned subject is annexed herewith.

This is for your information and record.

Thanking you.

Yours faithfully,  
For **Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Kundan Kumar Jha**  
*Company Secretary, Compliance Officer and Head-Legal*

Encl: as above

---

**Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Corporate Office:** 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSILC, Raidurg, Hyderabad - 500081, Telangana.  
Tel: +91 40 2354 9414 / 3311

**Regd. Office:** 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.  
Tel: 022 65139999

CIN: L24299MH2018PLC422236 | Website: [www.cohance.com](http://www.cohance.com) | Company Email: [reachus@cohance.com](mailto:reachus@cohance.com)



**Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

1	Name	<b>Mr. Sunil Kumar Singh</b>
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Sunil Kumar Singh, Chief Quality Officer, as Senior Management Personnel of the Company, with effect from January 19, 2026.
3	Date of appointment/ re-appointment/ cessation (as applicable) & term of appointment/ re-appointment	Mr. Sunil Kumar Singh, Chief Quality Officer, has been appointed as Senior Management Personnel of the Company, with effect from January 19, 2026.
4	Brief Profile (in case of appointment)	Brief profile is annexed herewith
5	Disclosure of relationship between directors (in case of appointment)	Not applicable

**Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Corporate Office:** 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.  
Tel: +91 40 2354 9414 / 3311

**Regd. Office:** 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.  
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: [www.cohance.com](http://www.cohance.com) | Company Email: [reachus@cohance.com](mailto:reachus@cohance.com)



## Profile of Mr. Sunil Kumar Singh



Mr. Sunil Kumar Singh joined the Company in December 2025 as Chief Quality Officer.

Mr. Sunil brings over 35 years of extensive leadership experience in pharmaceutical quality across APIs, formulations, CDMO and external manufacturing ecosystems. In his most recent role, he served as Global Head – Quality for the PSAI Business at Dr. Reddy’s Laboratories, with an enterprise-wide mandate as Global Head – Internal Audit & Compliance.

His experience spans diverse areas of pharmaceutical quality and compliance. He has a proven track record in building future-ready quality organizations, strengthening regulatory trust, and enabling business growth through science-driven quality transformation, digitalization and proactive risk governance. He is widely trusted by global regulators and senior leadership to lead quality beyond compliance and position it as a strategic business enabler.

With a proven ability to navigate challenges and deliver impactful results, he has worked with leading pharmaceutical multinational companies including Mylan, Zydus, Glenmark and Cipla.

Mr. Sunil’s holds a Master’s degree in Management and B.Sc. (Tech) - Pharmaceuticals and Fine Chemicals.

